Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Discovery of MK-8831, A Novel Spiro-Proline Macrocycle as a Pan-Genotypic HCV-NS3/4a Protease Inhibitor

22 Dec 2015

Abstract excerpt

We have been focused on identifying a structurally different next generation inhibitor to MK-5172 (our Ns3/4a protease inhibitor currently under regulatory review), which would achieve superior pangenotypic activity with acceptable safety and pharmacokinetic profile. These efforts have led to the discovery of a novel class of HCV NS3/4a protease inhibitors containing a unique spirocyclic-proline structural motif....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hepatitis C virus research
Share to HIV/AIDS drug development and treatment
Share to Monoclonal and Polyclonal Antibodies Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26819676
DOI: 10.1021/acsmedchemlett.5b00425

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Discovery of MK-8831, A Novel Spiro-Proline Macrocycle as a Pan-Genotypic HCV-NS3/4a Protease InhibitorPMID 26819676Read ↗

P2-quinazolinones and bis-macrocycles as new templates for next-generation hepatitis C virus NS3/4a protease inhibitors: discovery of MK-2748 and MK-6325.Semantic proximity Read ↗

MK-8325: A silyl proline-containing NS5A inhibitor with pan-genotype activity for treatment of HCV.Semantic proximity Read ↗

MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants.Semantic proximity Read ↗

Discovery of silyl proline containing HCV NS5A inhibitors with pan-genotype activity: SAR development.Semantic proximity Read ↗

Discovery and Characterization of Potent Pan-Genotypic HCV NS5A Inhibitors Containing Novel Tricyclic Central Core Leading to Clinical Candidate.Semantic proximity Read ↗

Novel spiroketal pyrrolidine GSK2336805 potently inhibits key hepatitis C virus genotype 1b mutants: from lead to clinical compound.Semantic proximity Read ↗

Development of potent macrocyclic inhibitors of genotype 3a HCV NS3/4A protease.Semantic proximity Read ↗

Synthesis, biological evaluation and in silico modeling of novel pan-genotypic NS5A inhibitors.Semantic proximity Read ↗

Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity.Semantic proximity Read ↗

Expanding the chemical space of anti-HCV NS5A inhibitors by stereochemical exchange and peptidomimetic approaches.Semantic proximity Read ↗

Highly potent HCV NS4B inhibitors with activity against multiple genotypes.Semantic proximity Read ↗

GSK2818713, a Novel Biphenylene Scaffold-Based Hepatitis C NS5A Replication Complex Inhibitor with Broad Genotype Coverage.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.